<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>23540987</identifier>
<setSpec>1138-3593</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Calvo Romero, J M</dc:author>
<dc:author>Lima Rodríguez, E M</dc:author>
<dc:description xml:lang="en">Rivaroxaban is a direct inhibitor of activated factor X, and dabigatran is a direct inhibitor of thrombin. These new oral anticoagulants have demonstrated to be effective and safe in clinical trials on the treatment of venous thromboembolic disease (deep vein thrombosis and pulmonary thromboembolism).</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2013 Apr </dc:date>
<dc:title xml:lang="es">Nuevos anticoagulantes orales en el tratamiento de la enfermedad tromboembólica venosa.</dc:title>
<dc:title xml:lang="en">[New oral anticoagulants in the treatment of venous thromboembolic disease].</dc:title>
<dc:publisher>Semergen</dc:publisher>
</metadata>
</record>
</pubmed-document>
